Who are Entrada Therapeutics, Inc.'s investors?

Entrada Therapeutics, Inc.'s investors include 5AM Ventures, Agent Capital, MPM BioImpact, MRL Ventures Fund, Roche Venture Fund, TCG Crossover, Wellington Management.

How much funding has Entrada Therapeutics, Inc. raised?

Entrada Therapeutics, Inc. has disclosed $150.9M raised across 3 of its 6 known rounds.

Where is Entrada Therapeutics, Inc. headquartered?

Entrada Therapeutics, Inc. is headquartered in Boston, US.

Entrada Therapeutics, Inc.

NASDAQ: TRDA

Boston, US · Founded 2016 · Delaware corporation · 7 known investors

Find your way into Entrada Therapeutics, Inc.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Entrada Therapeutics, Inc. team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.

Biotech Healthtech

Founders & leadership

Natarajan SethuramanExecutive

Nerissa Kreher Chief Medical Officer2020–2024Nerissa Kreher is a board-certified pediatric endocrinologist with experience in academic research, clinical practice, and biotechnology, including roles in medical affairs and clinical development. She holds an MBA and has expertise in rare disease therapeutics.

Kory Wentworth Chief Financial Officer and TreasurerKory Wentworth held senior finance leadership roles at research and commercial-stage biotech companies and Big 4 public accounting firms, with experience managing cross-functional teams and supporting global product launches and operational scaling. He serves as an Executive Officer at Entrada Therapeutics, which develops intracellular therapeutics for previously difficult-to-target diseases.

Dipal Doshi Chief Executive Officer & Board MemberDipal Doshi has nearly 30 years of experience in the life sciences industry, including roles in business development, corporate strategy, and product commercialization at companies including Amicus Therapeutics and Catalent, and holds an MBA from Wharton and a BA from Rutgers University. He has been Chief Executive Officer of Entrada Therapeutics since 2017, building the clinical-stage biotech company focused on developing intracellular therapeutics.

Natarajan Sethuraman, PhDPresident of Research and Development

Nathan J. Dowden President and Chief Operating OfficerNathan Dowden is President and Chief Operating Officer of Entrada Therapeutics. He brings 30 years of healthcare strategy and operations experience, including prior roles leading corporate development at Rubius Therapeutics, heading a life sciences consulting practice at Huron, founding and selling The Frankel Group, and positions at Ernst & Young, Searle Pharmaceuticals, and CIGNA Healthcare.

Kory Wentworth, CPAChief Financial Officer

Jared Cohen, PhD, JDGeneral Counsel

Karla MacDonaldChief Corporate Affairs Officer

Board

Carole Nuechterlein Board directorHead of Roche Venture Fund at Roche Venture Fund

Kush M. Parmar Chairman Of The Board Of DirectorsManaging Partner at 5AM Ventures

Todd Foley Board directorManaging Director at MPM BioImpact

Investors · 7

5AM Ventures✓ confirmed by Entrada Therapeutics, Inc.San Francisco · $100K – $4Mvia Kush M Parmar · board

How we know: the company's own site · the S-1 prospectus · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us

Agent Capitallisted by Agent CapitalWaltham

How we know: Agent Capital's portfolio page · the VCSheet dataset · Not right? Tell us

MPM BioImpactlisted by MPM BioImpactBoston · $1M – $15Mvia Todd Foley · board

How we know: MPM BioImpact's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us

MRL Ventures Fundlisted by MRL Ventures FundCambridge · $25M

How we know: MRL Ventures Fund's portfolio page · the S-1 prospectus · Not right? Tell us

Roche Venture Fundlisted by Roche Venture FundBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · Not right? Tell us

TCG Crossoverlisted by TCG CrossoverPalo Alto

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$150.9M disclosed across 3 of 6 rounds · 1900–2021

▶$116.2MraisedApr 2021 · 26 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Carole NuechterleinDirector
Natarajan SethuramanExecutive Officer
Kush M. ParmarDirector
Todd FoleyDirector
Peter KimDirector
Nerissa KreherExecutive Officer
Kory WentworthExecutive Officer
Dipal DoshiExecutive Officer, Director
John F. CrowleyDirector
Nathan DowdenExecutive Officer

Offering amount: $116.2M
Amount sold: $116.2M
First sale: Mar 2021
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$34MraisedDec 2019 · 10 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Natarajan SethuramanExecutive Officer
John CrowleyDirector
Nathan DowdenExecutive Officer
Louis TartagliaDirector
Kush ParmarDirector
Christine BrennanDirector
Anja HarmeierDirector
Dipal DoshiExecutive Officer, Director
Todd FoleyDirector
Mario SaltarelliExecutive Officer

Offering amount: $59M
Amount sold: $34M
Proceeds to insiders: $3.4M
First sale: Dec 2018
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$600KraisedNov 2016 · 2 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Kush ParmarExecutive Officer, Director
Louis TartagliaExecutive Officer, Director
Dehua PeiDirector

Offering amount: $1.6M
Amount sold: $600K
First sale: Oct 2016
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$598.7Mvaluation at IPONov 2021 · $20.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Entrada Therapeutics, Inc. went on to found or lead other companies.

Todd FoleyDirectorFounded Aktis Oncology Kush M ParmarDirectorFounded Homology Medicines

Related companies · 1

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies working in the same space as Entrada Therapeutics, Inc..

Frequently asked questions

What does Entrada Therapeutics, Inc. do?: Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
Who are Entrada Therapeutics, Inc.'s investors?: Entrada Therapeutics, Inc.'s investors include 5AM Ventures, Agent Capital, MPM BioImpact, MRL Ventures Fund, Roche Venture Fund, TCG Crossover, Wellington Management.
How much funding has Entrada Therapeutics, Inc. raised?: Entrada Therapeutics, Inc. has disclosed $150.9M raised across 3 of its 6 known rounds.
Where is Entrada Therapeutics, Inc. headquartered?: Entrada Therapeutics, Inc. is headquartered in Boston, US.